Does Asthma Phenotype Have Impact on Disease Control

Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyper Responsiveness Ensure Stable Disease Faster

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01978678

Acronym

Aperitif

Enrollment

Registered

2013-11-07

Start date

2012-11-30

Completion date

2015-01-31

Last updated

2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The application of biomarkers that are more closely associated with eosinophillic airway inflammation, such as measurements of FeNO level, cell count in induced sputum or bronchial reactivity could improve asthma control by better directing treatment. A systematic review and meta-analysis is to be conducted to assess the efficacy of tailoring asthma intervention on clinical symptoms compared with exhaled nitric oxide or induced sputum count.

Detailed description

AHR used as outcome

Interventions

DRUGPulmicort

ACQ and FeNO

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 100 Years

Healthy volunteers

Inclusion criteria

* positiv mannitol * asthma diagnose

Exclusion criteria

* other lung disease

Design outcomes

Primary

Measure	Time frame	Description
Control of asthma based on an algorithm	2 years	Based on ACQ and FeNO

Secondary

Measure	Time frame	Description
The use of NO and sputum cell count as a marker in asthma management	2 years	Based on ACQ and FeNO

Other

Measure	Time frame	Description
the use of ACQ and miniAQLQ	2 years	Based on ACQ and FeNO

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026